doi: 10.3389/fimmu.2026.1730351 Received 22 October 2025 Revised 28 January 2026 Accepted 24 February 2026 Published 25 March 2026 Volume 17 - 2026 Edited by Chafia Touil-Boukoffa, University of Science and Technology Houari Boumediene, Algeria Reviewed by Nar Singh Chauhan, Maharshi Dayanand University, India Fatma Naz Cemre Kalayci, DanaFarber Cancer Institute, United States Updates Copyright 2026 Zhan, Wang, Zhan, Yang, Liang, Yu and Wang
Thus, to highlight possible application of pentadecapeptide BPC 157 in both IBD and multiple sclerosis patients, this study shows BPC 157's potential to counteract the consequences of the cuprizone application, used in an extremely high regimen that highly exceeds those commonly applied (62)
The side effect profiles differ , but the injection technique does not
Interpret your results